TAK-700 in Castration Resistant Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH (luteinizing hormone-releasing hormone) agonists or surgical castration.
Epistemonikos ID: 565491c082b9b4868534fb17f9d71785e9a94f11
First added on: May 11, 2024